Ten months after it began its review of gadolinium contrast agents, the European Medicines Agency (EMA) has announced it is still continuing to assess the risk of gadolinium being deposited in brain tissue following MRI scans.
At its monthly meeting last week, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) listed gadolinium contrast agents as an ongoing referral that remains under evaluation.
Once its review has been completed, the PRAC committee will forward its recommendations to the agency's Committee for Medicinal Products for Human Use, which will adopt a final opinion, according to the EMA. The European Commission will then complete the review process by adopting a legally binding decision that's applicable in all European Union member states.
